Market News

The Wear Indicator Layer is expected to have a "huge impact" on customers' production.

Company has developed a standard feature for its customers to execute the EMVO conformance testing successfully.

TAOS matrix system and products hailed as potential ‘game changers’ in the field of regenerative medicine.

‘Brexit taskforce’ will see Recipharm prioritise its preparations and invest in the necessary capabilities and equipment to ensure seamless operations post March 2019.

Forgotten markets of Africa and Arabia to see increased growth fuelled by international and domestic partnerships and imported APIs.

Company to streamline operations and capture cost synergies.

Testa Anayltical to discuss their latest developments and application advances in Light Scattering technology, GPC/SEC instrumentation and Zeta potential measurement.

New equipment allows Genvion to take customers from development through to commercial manufacture.

Tjoapack to perform the secondary packaging and assembly of product kits for supply to 25 European countries, the US, Canada and Australia.

New poster describes how the EAF4 module enabled simultaneous measurement of size and surface charge characteristics of antibodies and proteins.

Bosch's new Xelum R&D for continuous production of oral solid dosage forms ensures a short time-to-market and optimum dosing of APIs.

2018 event prepares for surge in international attendees as MAH nears national rollout.

Postponement printing is presenting interesting benefits for the pharmaceutical supply chain.

With the capacity expansion, Thermo Fisher will have the second largest base of single-use bioproduction capacity at a CDMO in the world.

Acquisition of AurKa Pharma expands Lilly's oncology pipeline with early-phase asset being studied in multiple tumour types.

Recipharm's Staffan Widengren, Director Corporate Projects, discusses why CMOs should be focusing on the value-added opportunities presented by serialisation.

Allows for easy and intuitive scale-up from research.

Customers to gain a greater insight into their projects, better track project progress and improve communications.

Managing the risks associated with Industrial Hygiene and Quality and meeting operational efficiency targets.

New Industry 4.0 solutions from Bosch for more transparency.

Acquisition enables Ardena to manufacture batch sizes up to 100 kg.

Anmeal and Impax create diversified pharmaceutical company.

The integrated R&D and manufacturing facility is expecting more products to go into commercial production post approval.

Noramco and SPI Pharma sign agreement to develop ready-to-implement, patient-friendly formulations for pharmaceutical manufacturers.

Integrated one-site solution for partners to push forward innovative APIs and advanced intermediates from preclinical to commercial stage.

Energy efficient, short cycle times and reliable product quality in large batches.

Company to bring its new services and products into the spotlight at ACHEMA.

The CDMO's US sales have increased from £15.5 million to £41 million since 2016.

Sartorius Stedim Biotech introduces its mini microcarrier bioreactor for culturing adherent cells.

Investment enhances the CDMO's scale-up and small to midscale commercial API manufacturing capabilities.

The contract manufacturer strengthens its pharmaceutical-protein business with Dutch acquisition

MD-026 is the first RSK inhibitor to demonstrate potential disease-modifying properties in triple-negative breast cancer.

Sale of oncology business unlocks embedded value within Shire’s portfolio and sharpens focus on core areas reinforcing the company's leadership in rare diseases.

Investment will focus on the rapid and successful development of processes to supply clinical and commercial demand for chemical syntheses.

Carbon footprint reduced by more than 70%.

Expansion meets the demand for additional capacity to serve large-scale clinical studies and provides the space for future growth.

NIH-funded study finds omega-3 fails to yield beneficial results in the clinic.

New Toronto facility is one of the largest-ever investments by Sanofi in a single building.

Purpose-built compliance solution for smaller pharmaceutical companies.

First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.

SVP250 LF processing system minimizes product loss thanks to conical vessel shape.

Revolutionary, innovative plant offers greater flexibility, speed and efficiency.

The event will annually switch between Indonesia and Thailand to cater to attendees that were previously unable to participate.

The IHD series has been specially designed for coating and granulating pharmaceutical products with hot greases and waxes.

Pharma Liquid World shows the connection of a preparation system and filling machine, as well as robotic technology in aseptic filling.

The company’s environmental efforts honored for the fourth consecutive year.

With the acquisition of Irvine Scientific, FujiFilm will have a full product line supporting customers supplying antibody drugs to assisted reproductive technologies and cell therapy.

The investment makes Idifarma one of only three companies in the world offering this type of contract development and manufacturing spray drying service.

Customers stand to benefit from broader services covering their API, drug product, regulatory CMC and bioanalysis requirements.

Expansion increases the facility’s manufacturing capacity by 200 million unidoses/year.

Global analysis will rank each major biomanufacturing country’s market growth potential, innovation and competitiveness.

Extensive range of ready-to-use culture media available in bottles and plates.

Additional capacity expansion across several of the company's sites also strengthens the company's global market leadership in spray drying.

Bio and generic demand reflective of wider trends in the market – with overseas investments now prospering.

Unique, single-use perfusion system offers a fast-track to intensified cell culture process development.

Four out of 10 of the top selling facial scrub brands use clay, sugar, salt or fruits as alternatives to microbeads.

Manufacturing high potency drugs - the challenges and innovations to mitigate the risks.

Noramco selects AFC for its infrastructure and analytical capabilities to help meet growing demand.

Partnership enables production volumes of NLAB Saga chromatography material to increase from tens of kilograms to tens of tonnes.

PF-04958242 is an AMPA receptor potentiator designed to facilitate neurotransmission.

MedPharm invests in $0.75 million cutting-edge instrumentation to further automated testing and expands workforce.

Experts forecast the personalised medicines, intelligent packaging and regulatory deadlines as the industry's biggest development.

The agreement includes the manufacture of 600 million enteric, chewable and film-coated tablets.

Licensing agreement enables Recipharm to co-develop new value-added medicines for its customers utilising Altus’ patented Intellitab and Flexitab drug delivery technologies.

ASEAN Economic Community and relaxed rules on foreign ownership driving increases in international investment and partnerships.

Expansions to meet safety requirements for GMO S2 and BSL-2 biological products.

Customers to have the option of one partner from concept to market for their encapsulated drug products

Proposed acquisition of Viralytics will add investigational oncolytic immunotherapy, Cavatak, to Merck's pipeline.

The SupaPore VPBA filter enabled 30% faster processing times than the company's current regime.

Gaining GLP/GMP accreditation to provide greater assurance of data integrity for clients looking to take their compounds to IND.

Agreement follows the recent opening of WuXi STA's oligonucleotide R&D labs in China and the US.

BASF's Hepaxa is the first product in the US specifically designed to address a buildup of fat in the liver in NAFLD patients.

The Centers of Excellence will allow custoners to access customer-centric solutions.

Vetter innovations in aseptic production increases the competitiveness of its customers.

The scientific, chemical and pharmaceutical expertise will cover end-to-end development services, ranging from development of the active compound to providing dossiers for marketing authorisation applications in all major geographies.

Expansion will accommodate new scientists to service the increase in demand for the company's formulation development, performance testing and manufacturing services.

Screening for new marine-derived functional ingredients and bringing new patented products to the market.

Packaging innovation shows a clear focus on patient compliance and ease-of-use.

New manufacturing paradigm will save 25% of total costs and the need for proteinaceous A & G resins.

What does a good supplier look like? Andrew Ramage, Microbiology Product Specialist at Cherwell Laboratories, advises how to take the guesswork out of the search.

Successful MHRA inspection at Dundee site confirms GLP accreditation for in vitro safety studies and bioanalysis.

Investment will enable Idifarma to both serialise commercial batches manufactured by them for clients and offer standalone serialisation services.

Funding will support further development of recently acquired small molecule assets for treatment of autoimmune disease.

PAA showcases its complete range of automation solutions, suitable for any type of laboratory or application, at SLAS2018.

Company also promoted to Platinum supplier status in Europe.

A new analytical tool, Electrical Asymmetrical Flow Field-Flow Fractionation (EAF4) is showing much promise in biopharmaceutical and nanoparticle applications.

Pall Biotech to focus on enabling drug manufacturers to rapidly transition from pre-clinical to commercial manufacturing.

Love it or loathe it, plastic is here to stay, but that doesn't let the pharmaceutical industry off the hook.

The expansion at Charles City is in parallel to the investments announced in 2017 at Cambrex’s facility in High Point, North Carolina.

Strengthens Sanofi's R&D strategy with innovative Nanobody technology platform.

Forté Pharma's new nutritional supplement combines natural extracts: valerian, passionflower, and vitamins B3 and B6, which contribute to prolong sleep for 8 hours.

The companies have 15 days to respond to the FDA and FTC.

Enamine REAL database of synthetic compounds accessible via UCSF’s online ZINC platform.

Commercial manufacturing of Cinryze drug product in Vienna to begin in the first quarter of 2018.

LifeArc and Milner Therapeutics Institute to develop, validate and integrate cutting-edge machine learning approaches into drug discovery processes.

Sanofi to acquire Bioverativ for $11.6 billion.

Collaboration will leverage combined strengths of development, manufacturing and commercialization of biosimilars.

KWS increases Charles River's ability to support clients’ early-stage drug research in critical therapeutic areas.

With time running out, Meditraq launches to simplify serialisation data challenge.

Through the acquisition of Nautilus Biosciences, Croda will utilise the company's innovative science for applications across all its market sectors.

Opening ceremony marks long-term supply agreement between Cambrex and AstraZeneca for a key intermediate.

New Year CPHI Japan report predicts 2018 will be a transformative year for Japanese pharma, with early movers likely to benefit.

A summary and highlights of new drug therapy approvals and other drug therapy advances in 2017 by FDA's CDER.

Three anti-ageing and anti-stress active ingredients for manufacturers of skin care product

The MedStat-HT and MedFlux-HT help to de-risk development programs and shorten development timelines.

The new formulation is proven to reduce blood sugar levels and may have the added benefit of weight loss.

New 3D technology provides a powerful platform for skin care researchers wishing to study the function of sebaceous glands, in relation to a range of age-related, microbial and inflammatory skin disorders.

Health investors are paying attention to Canada, particularly to Toronto’s hot market.

Acquisition will expand Takeda’s late-stage pipeline and leadership in gastroenterology.

"The precision and flexibility of zinc finger proteins enables targeting of virtually any genetic mutation."

SSB will provide both facilities with end-to-end process solutions in single-use format.

Targeting the initiation of a pivotal patient clinical trial in the first half of 2018.

Ideal for a wide variety of pharmaceutical applications.

SRK-015 to move into clinical development for Spinal Muscular Atrophy (SMA) in first half of 2018; development in additional neuromuscular disorders to follow.

The transaction will allow Recipharm to combine and better exploit operational synergies with the company's other Indian business.

Martyn Davies recognised for his contribution to UK science and his ground-breaking achievements in pharmaceutical research and drug development.

Company envisions the development and IND filings of multiple “next-frontier” CAR-T programs in 2018 and beyond, which will position the company as a potential major player in the fast-growing CAR-T space of immunotherapies against cancers.

Libbs will commercialize the product in Brazil under the brand name Zedora.

Mylan now offers estradiol in four delivery methods.

The additional capacity from this site is a key element to support the growth in the company's Immunology franchise.